Candidemia subsequent to severe infection due to Clostridium difficile: Is there a link?

Clinical Infectious Diseases

Volumn 57, Issue 5, 2013, Pages 772-774

  Guastalegname, Maurizio ^a   Russo, Alessandro ^a   Falcone, Marco ^a   Giuliano, Simone ^a   Venditti, Mario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CEFTRIAXONE; CIPROFLOXACIN; FLUCONAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MICAFUNGIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BLOODSTREAM INFECTION; CANDIDA; CANDIDEMIA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTION; FECES; GASTROINTESTINAL CANDIDIASIS; GASTROINTESTINAL MUCOSA; HUMAN; INVASIVE CANDIDIASIS; LETTER; MUCOSAL IMMUNITY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RELAPSE; RIBOTYPING;

AMINOGLYCOSIDES; CANDIDA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROCOCCUS; FEMALE; HUMANS; MALE; VANCOMYCIN;

EID: 84881439272     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit362     Document Type: Letter

References (10)

1. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 2012; 55(suppl 2):S121-6.
2. Manian FA, Bryant A. Does Candida species overgrowth protect against Clostridium difficile infection?. Clin Infect Dis 2013; 56:464-5.
3. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431.
4. Di Bella S, Paglia MG, Johnson E, Petrosillo N. Clostridium difficile 027 infection in central Italy. BMC Infect Dis 2012; 12:370.
5. Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: From the laboratory to the bedside. Clin Infect Dis 1996; 22:S73-88.
6. Madan R, Petri WA Jr. Immune responses to Clostridium difficile infection. Trends Mol Med 2012; 18:658-66.
7. El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 2013; 56:1713-21.
8. Nam HJ, Kang JK, Kim SK, et al. Clostridium difficile toxin A decreases acetylation of tubulin, leading to microtubule depolymerization through activation of histone deacetylase 6, and this mediates acute inflammation. J Biol Chem 2010; 285:32888-96.
9. Chumbler NM, Farrow MA, Lapierre LA, et al. Clostridium difficile toxin B causes epithelial cell necrosis through an autoprocessingindependent mechanism. PLoS Pathog 2012; 8:e1003072.
10. Brito GA, Sullivan GW, Ciesla WP Jr, Carper HT, Mandell GL, Guerrant RL. Clostridium difficile toxin A alters in vitro-adherent neutrophil morphology and function. J Infect Dis 2002; 185:1297-306.